Cancer Clinical Trials


  • Alliance A011202 - A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

  • CINJ 040406-4862 - Effect of DNA Variations on Breast Cancer Risk and Recurrence

  • CINJ 130404 - Women’s Circle of Health Study (Breast Cancer Study in African American Women)

  • ECOG 2112 - A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer

  • Novartis CLEE011A2301 - A Randomized Double-Blind, Placebo-Controlled Study of LEE011 In Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer Who Received No Prior Therapy For Advanced Disease (Closed to Enrollment, Effective February 6, 2015)

  • Novartis CLEE011E2301 - A Phase III Randomized, Double-Blind, Placebo-Controlled Study of LEE011 Or Placebo in Combination With Tamoxifen and Goserelin or a Non-Steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer (Closed to Enrollment)

  • Novartis CLEE011F2301 - A Randomized Double-Blind, Placebo Controlled Study of Ribociclib In Combination With Fulvestrant for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer Who Have Received No Or Only One Line Of Prior Endocrine Treatment (Monaleesa-3)(Closed to Enrollment)

  • Puma 3144A2-3004-WW - A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer (Closed to Enrollment)

  • Puma Puma-NER-6201 - An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

  • RCINJ 041401 - A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients with ER, PR, HER2 Negative Breast Cancer (TNBC)

  • RTOG 1304 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy


  • BMS CA209-577 - A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer

  • Gilead GS-US-296-1080 - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  • RTOG 1112 - Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib in Hepatocellular Carcinoma


  • Bayer REASSURE - Radium-223 Alpha Emitter Agent in Non-Intervention Safety Study in mCRPC Population for Long-Term Evaluation

  • RCINJ 131023 (COUPLES) - Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer

  • RCINJ 131107 (PROGRESS) - Randomized Controlled Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors PROGRESS – PRostate Cancer Online Guide & Resources for Electronic Survivorship Service)


  • GOG 0225 - Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube And Primary Peritoneal Cancer Progression-Free Survival?

Head and Neck

  • Galera GT-201 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis (OM) in Patients Receiving Post-Operative or Definitive Therapy with Single-Agent Cisplatin plus IMRT for Locally Advanced, Non-Metastatic Squamous Cell Carcinoma of the Oral Cavity or Oropharynx


  • Pharmacyclics PCYC-1134M-CA - informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia


  • Accuray ReCKord - CyberKnife Registry Protocol

  • RCINJ 001209 (PRECISION) - Targeted Genomic Analysis of Human Cancer


  • Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

  • JoLT-Ca STU 022015-069 - A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

  • Oncocyte PRO068 - A Study to Evaluate a Panel of Blood Biomarkers For Use In Patients Undergoing Evaluation For Lung Cancer, ONC-LN-04

  • OSE Pharma OSE2101C301 - A Randomized Parallel Group Phase III Trial of OSE 2101 as 2nd Line After Prior Platinum-Based Chemotherapy Failure or as 3rd Line After Platinum-Failure and Checkpoint Inhibitor-Failure, Compared With Standard Treatment (Docetaxel or Pemetrexed) In HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable For Radiotherapy or Metastatic Non-Small-Cell Lung Cancer. (OSE2101C301)

  • SWOG S1400 - Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (LUNG-MAP)[Closed to Enrollment - S1400A, Arm 2-Docetaxel and S1400E; Temporarily Closed to Enrollment - S1400C]


  • ECOG-ACRIN 6134 - A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab At Progression vs. Ipilimumab + Nivolumab Followed By Dabrafenib + Trametinib At Progression in Patients With Advanced BRAFV600 Mutant Melanoma